Clinical Trial Results: Spondylitis, Ankylosing

Protocol Number: NA22823

Product Name: RoActemra/Actemra [tocilizumab [RoActemra/Actemra]]

Date of Report: 01.09.2012

Phase: III

A Phase II/III seamless, multi-center, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with tocilizumab versus placebo in patients with ankylosing spondylitis who have failed non-steroidal anti-inflammatory drugs and are naïve to TNF antagonist therapy
Protocol Number: WA22908

Product Name: RoActemra/Actemra [tocilizumab [RoActemra/Actemra]]

Date of Report: 01.09.2012

Phase: III

A randomized, double-blind, parallel group placebo-controlled study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) versus placebo in patients with ankylosing spondylitis who have had an inadequate response to previous TNF antagonist therapy

This database is populated with information on the results of Roche-sponsored clinical trials.

Roche trials database